# Moleculin Biotech

Source: https://onco.cc/companies/moleculin/  
OnCo record `moleculin` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Moleculin is a Houston biotech whose annamycin, an anthracycline designed to spare the heart, is in a phase 3 trial with cytarabine for relapsed acute myeloid leukaemia.

## Summary

Moleculin Biotech, headquartered in Houston, Texas, licenses drug candidates from MD Anderson Cancer Center. Its lead, annamycin, is a liposomal anthracycline engineered to avoid the cardiotoxicity of doxorubicin and to evade multidrug resistance pumps, and is in the phase 3 MIRACLE trial with cytarabine in relapsed or refractory acute myeloid leukaemia; WP1066, a STAT3 inhibitor, is in earlier trials in brain tumours. Its trials are registered on ClinicalTrials.gov under Moleculin as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Moleculin Biotech, Inc.; Moleculin
- Tags: ctgov-sponsor
- HQ: Houston, TX
- Type: biotech
- Website: https://www.moleculin.com

## Sources

- Official website: https://www.moleculin.com
- ClinicalTrials.gov: trials led by Moleculin Biotech, Inc.: https://clinicaltrials.gov/search?lead=Moleculin%20Biotech%2C%20Inc.

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- institutions: [MD Anderson Cancer Center](https://onco.cc/institutions/md-anderson/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/moleculin.json